Literature DB >> 10643850

Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.

F Hoffmann1, G Notheis, U Wintergerst, J Eberle, L Gürtler, B H Belohradsky.   

Abstract

BACKGROUND: In this retrospective study we compared the antiretroviral effect of regimens consisting of simultaneous administration of two protease inhibitors (PI) with at least one nucleoside reverse transcriptase inhibitor on plasma viral load (VL) and CD4 cell count in HIV-infected children intensively pretreated with nucleoside reverse transcriptase inhibitors and PIs.
METHODS: Eleven HIV-infected children were changed to antiretroviral combination regimens including two PIs and followed for a median time of 24 weeks. Group A comprised six patients who were given ritonavir + saquinavir (SQV) and Group B consists of five patients who were changed to nelfinavir + SQV. Patients were treated with these combinations with 2 PIs because of treatment failure (increasing viral load) of prior PI therapy or clinical signs of disease progression. OUTCOME MEASURES: Serial determinations of plasma viral load (Amplicor, Roche) and CD4 cells were performed every 4 to 8 weeks. The detection limit of the Amplicor-reverse transcriptase-PCR assay was 50 copies/ml (1.7 log10).
RESULTS: In Group A the median VL reduction was 1.1 log10 after 3 months and 1.4 log10 after 6 months. In Group B median VL decreased 0.1 and 0.2 log10 after 3 and 6 months. In both groups during the study period none of the patients reached undetectable VL. The relative changes of CD4 cells above baseline in Group A showed a median increase of 7% after 3 months and 23% after 6 months. In Group B after 3 months CD4 cells did not increase, and after 6 months the median relative increase was only 7%. Both combination therapies were well tolerated, not necessitating any drug interruption during study period.
CONCLUSIONS: In children with intensive prior antiretroviral treatment, a salvage therapy including two PIs demonstrated antiretroviral efficacy in some patients. In this study the reduction of the VL as well as the increase of CD4 cells was more pronounced with ritonavir + SQV than with nelfinavir + SQV. With both combinations complete suppression of HIV replication was not achieved. Therefore the long term effect of these combinations may be limited by the emergence of resistant HIV strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10643850     DOI: 10.1097/00006454-200001000-00010

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

Review 1.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 2.  Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: what are the issues and what can be done?

Authors:  Emanuele Pontali
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 3.  Nelfinavir: a review of its use in the management of HIV infection.

Authors:  Caroline M Perry; James E Frampton; Paul L McCormack; M Asif A Siddiqui; Risto S Cvetković
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Response to a protease-inhibitor (ritonavir)-containing combination antiretroviral regimen in HIV-infected children.

Authors:  Upton D Allen; Normand Lapointe; Stanley E Read; Jack C Forbes; Susan M King; Samia Wasfy
Journal:  Can J Infect Dis       Date:  2003-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.